Tumor necrosis factor (TNF) is cytotoxic for several transformed cell lines in vitro. In the presence of LiCI, the murine fibrosarcoma cell lines L929 and WEHI 164 done 13 became >10 times more sensitive to TNF-mediated cytotoxicity. The human tumor cell lines BT20 and HeLa D98/AH2 were also responsive to the cytotoxicity-enhancing effect of LiCI. Other monovalent or divalent cations did not affect TNF-mediated cytotoxicity. The potentiating effect of LiCI on TNF cytotoxicity was largely independent of transcription, and LiCl could be added to the cells as early as 2 hr before or as late as 4 hr after TNF without loss of effectiveness. The mechanism by which LiCI increases the cytotoxic response seems to differ from the sensitizing effect of actinomycin D or interferon y, since the latter treatments overcame TNF resistance of several cell lines, whereas LiCl did not. Evidence is presented that LiCl acts, either directly or indirectly, via the TNF-activated phospholipase A2 pathway. In nude mice, a combination ofTNF and LiCl led to hemorrhagic necrosis and growth inhibition of L929 tumors, whereas little effect was observed when TNF was administered alone. HeLa D98/AH2 tumors also were sensitive to the potentiating effect of LiCl in vivo. We conclude that LiCl enhances the effectiveness of TNF in vitro and in vivo, results that may have therapeutic implications.Tumor necrosis factor (TNF) is a cytokine that was originally identified in the sera of mice that had been primed with bacillus Calmette-Guerin and challenged with endotoxin. When injected into mice bearing methylcholanthreneinduced sarcomas, TNF causes hemorrhagic necrosis of the tumor (1). In vitro, TNF exerts cytostatic and cytotoxic activity against a wide range of human and murine tumor cell lines, although it has little or no antiproliferative activity on nontransformed cell lines (2, 3). However, not all tumor cells are sensitive to TNF-mediated cytotoxicity. The molecular mechanism for this difference in response still remains largely unknown. Recently, a serine-type protease was shown to be involved in TNF-mediated cytotoxicity (4). Furthermore, there is ample evidence for an activation of a phospholipase A2 (PLA2) activity (5, 6). In addition to its cytotoxic effect on transformed cells, TNF mediates a variety of other biological activities on various cell types, both in vivo and in vitro (7).In our efforts to understand the mechanism of action of TNF on malignant cells, we also evaluated a possible involvement of phospholipase C activity. In these experiments, we tested whether LiCl, which is known to inhibit inositol-1-phosphatase (8), would interfere with specific tumor cell killing by TNF. Surprisingly, we found instead that LiCl potentiated TNF-mediated cytotoxicity in vitro almost to a similar extent as has been shown before for actinomycin D (ActD) and cycloheximide (2) and, more physiologically, for interferon (IFN) (3, 9). Moreover, this LiCl-specific TNF potentiation can be extended to the in vivo antitumor action of TNF. Elsewh...